BC-CfE submitted Health Canada “Special Access Program” application to provide two investigational HIV drugs to six patients resistant to all other therapies. Health Canada denies the BC-CfE access and the BC-CfE publicly campaigns for access. Health Canada reverses its decision and the BC-CfE is first to prescribe the combination of TMC114 (darunavir) and TMC125 (etravirine) together to the remaining five patients.
BC-CfE’s research lab demonstrated the effect of impact of human and virus genetics in the response to HAART treatments.
BC-CfE launched large cohort of women in sex work to examine their sexual health and HIV needs and barriers to care.
CLICK FOR NEW HIV-1 RESISTANCE GENOTYPE REPORT NOTICE
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’. For more details and example reports, please click on the button below
